Recognizing Biopharma Industry Excellence

Published on: 
BioPharm International, BioPharm International-07-01-2016, Volume 29, Issue 7
Pages: 6

CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.

Each day, the editors of BioPharm International receive press releases promoting potential: announcements of new products, services, methods, and processes destined to solve a problem, cure a disease, save money, and-in some cases of extreme hyperbole-change the world.

As natural cynics, the editors question the validity of these projections of great success. We also appreciate the true successes, as recognized by independent evaluations by industry experts. The CPhI Pharma Awards are one such program to recognize excellence in biopharma development and manufacturing.

The awards program recognizes companies and individuals helping to accelerate the development of biopharmaceuticals through the introduction of innovations, new technologies, and strategies that support drug development, manufacturing, and distribution. The program is organized by CPhI Worldwide, a global tradeshow for the pharma industry, scheduled for Oct. 4-6, 2016 in Barcelona, Spain. CPhI and BioPharm International are UBM plc brands.
The 2016 awards are organized into 12 categories including:

Advertisement
  • Excellence in Pharma<: Bioprocessing. Technologies, products, processes, and services for the manufacture of biologic drugs.

  • Excellence in Pharma Contract Services & Outsourcing. Contracted services and processes for the bio/pharmaceutical industry including research, development, formulation, manufacturing, analysis, and consulting.

  • Excellence in Pharma: Regulatory Procedures and Compliance. Technologies, products, processes, and services designed to ensure that bio/pharma companies comply with standards,  rules, and guidances established by regulatory and compendial authorities.

  • Excellence in Pharma: Supply Chain, Logistics, & Distribution. Technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and drug products.

  • Excellence in Pharma: Analysis, Testing, and Quality Control. Technologies, products, processes, and services for the analysis and testing of drug substances, raw materials, and drug products in a laboratory or production-line setting.

  • Excellence in Pharma: Packaging. Technologies, products, processes, and services related to primary and secondary packaging.

  • Excellence in Pharma: Drug Delivery Devices. Technologies, products, processes, and services related to the delivery of drug products to patients.

  • Excellence in Pharma: Corporate Social Responsibility. Innovation in improving transparency and public outreach.

  • Excellence in Pharma: CEO of the Year. The chief executive officer of an innovator or generic-drug company is eligible for nomination. Attributes to be considered include financial performance, product performance, leadership skills, management capability, marketing, acquisitions, and corporate strategy.

  • Excellence in Pharma: API Development. Technologies, products, processes, and services for the development and manufacture of APIs.

  • Excellence in Pharma: Formulation and Excipients. Technologies, products, processes, and services related to the formulation of drug products.

  • Excellence in Pharma: Manufacturing Technology and Equipment. Technologies, products, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs.

Applications for the 2016 CPhI Pharma Awards must be submitted by Aug. 14, 2016 via the awards website at awards.cphi.com. Finalists will be announced in September 2016. The awards will be presented on Oct. 4, 2016 during the Pharma Awards Gala at CPhI Worldwide.

 

Article DetailsBioPharm International
Vol. 29, No. 7
Page: 6

Citation
When referring to this article, please cite it as R. Peters, " Recognizing Biopharma Industry Excellence," BioPharm International 29 (7) 2016.